CN1078388A - 应用透明质酸和nsaids治疗疾病 - Google Patents

应用透明质酸和nsaids治疗疾病 Download PDF

Info

Publication number
CN1078388A
CN1078388A CN 93101898 CN93101898A CN1078388A CN 1078388 A CN1078388 A CN 1078388A CN 93101898 CN93101898 CN 93101898 CN 93101898 A CN93101898 A CN 93101898A CN 1078388 A CN1078388 A CN 1078388A
Authority
CN
China
Prior art keywords
skin
hyaluronic acid
tissue
dosage
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 93101898
Other languages
English (en)
Chinese (zh)
Inventor
R·E·福尔克
S·S·阿素莱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NORPHARMCO Inc
Original Assignee
NORPHARMCO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NORPHARMCO Inc filed Critical NORPHARMCO Inc
Publication of CN1078388A publication Critical patent/CN1078388A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN 93101898 1992-02-20 1993-02-20 应用透明质酸和nsaids治疗疾病 Pending CN1078388A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002061566A CA2061566C (en) 1992-02-20 1992-02-20 Treatment of disease employing hyaluronic acid and nsaids
CA2,061,566 1992-02-20

Publications (1)

Publication Number Publication Date
CN1078388A true CN1078388A (zh) 1993-11-17

Family

ID=4149300

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 93101898 Pending CN1078388A (zh) 1992-02-20 1993-02-20 应用透明质酸和nsaids治疗疾病

Country Status (22)

Country Link
EP (1) EP0626864B1 (de)
JP (1) JP4005628B2 (de)
KR (1) KR100334973B1 (de)
CN (1) CN1078388A (de)
AP (1) AP476A (de)
AT (1) ATE244020T1 (de)
AU (2) AU3488993A (de)
CA (1) CA2061566C (de)
CZ (1) CZ290534B6 (de)
DE (1) DE69333072T2 (de)
DK (1) DK0626864T3 (de)
ES (1) ES2202311T3 (de)
HK (1) HK1005982A1 (de)
HU (2) HU225963B1 (de)
IL (1) IL104797A0 (de)
MX (1) MX9300905A (de)
NZ (2) NZ299281A (de)
PT (1) PT626864E (de)
SG (1) SG49874A1 (de)
SK (1) SK11093A3 (de)
WO (1) WO1993016733A1 (de)
ZA (1) ZA931174B (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102961396A (zh) * 2012-12-17 2013-03-13 程玉李 透明质酸金属盐在制备治疗皮肤病药物中的应用、其药物组合物及其制备方法
CN104689460A (zh) * 2004-12-30 2015-06-10 建新公司 用于关节内粘弹性补充的方案
CN105473146A (zh) * 2013-06-13 2016-04-06 东亚St株式会社 含有吡罗昔康和透明质酸的用于治疗骨关节炎的液态药物组合物
CN106729644A (zh) * 2016-11-22 2017-05-31 郑州兰茜生物工程有限公司 一种温和多效消疣剂及其制备方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
EP0952855B1 (de) * 1991-07-03 2005-07-27 Meditech Research Limited Verwendung von hyaluronan in gentherapie
CA2094203A1 (en) * 1993-04-16 1994-10-17 Derek A. Willoughby Inhibition of angiogenesis
WO1996004922A1 (en) * 1994-08-10 1996-02-22 Davis, Joanne, T. Method of using hyaluronic acid for the detection, location and diagnosis of tumors
CA2154103C (en) * 1995-07-18 1998-02-24 Samuel Simon Asculai Treatment of mucous membrane disease, trauma or condition and for the relief of pain
EP0852501B1 (de) * 1995-09-28 2004-12-01 Sangstat Medical Corporation Verwendung von hyaluronsäure als immunsuppessor
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
US5939047A (en) * 1996-04-16 1999-08-17 Jernberg; Gary R. Local delivery of chemotherapeutic agents for treatment of periodontal disease
US6630168B1 (en) 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
CA2370003C (en) 1999-01-13 2008-08-19 Tracey Brown A composition and method for the enhancement of the efficacy of drugs
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US6576226B1 (en) 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US6726898B2 (en) 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
CA2616607C (en) 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
JP5627181B2 (ja) 2005-09-07 2014-11-19 アルケミア オンコロジー ピーティーワイ リミテッド ヒアルロナンおよび治療用抗体を含む治療用組成物ならびに治療方法
EA015702B1 (ru) * 2007-05-28 2011-10-31 Винченцо Массимо Ломбардо Противовоспалительная и анальгетическая композиция для местного применения в области опорно-двигательного аппарата животного
WO2010069519A1 (en) 2008-12-18 2010-06-24 Merz Pharma Gmbh & Co. Kgaa Topical compositions comprising at least one active ingredient poorly soluble in water and biopolymers such as hyaluronic acid with a pka-value between 5-7
WO2012119261A1 (en) * 2011-03-10 2012-09-13 Biocia Inc. Enhanced artificial mucus composition comprising hyaluronan for the treatment of rhinitis
FR2994846B1 (fr) 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium
CA2968357A1 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
IT201600079633A1 (it) * 2016-07-28 2018-01-28 Fidia Farm Spa Procedimento di preparazione e purificazione del sale sodico dell’acido ialuronico

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
IN166447B (de) * 1985-11-27 1990-05-12 Ethicon Inc
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104689460A (zh) * 2004-12-30 2015-06-10 建新公司 用于关节内粘弹性补充的方案
CN102961396A (zh) * 2012-12-17 2013-03-13 程玉李 透明质酸金属盐在制备治疗皮肤病药物中的应用、其药物组合物及其制备方法
CN105473146A (zh) * 2013-06-13 2016-04-06 东亚St株式会社 含有吡罗昔康和透明质酸的用于治疗骨关节炎的液态药物组合物
CN106729644A (zh) * 2016-11-22 2017-05-31 郑州兰茜生物工程有限公司 一种温和多效消疣剂及其制备方法

Also Published As

Publication number Publication date
CZ290534B6 (cs) 2002-08-14
AU3488993A (en) 1993-09-13
DE69333072T2 (de) 2004-04-22
ES2202311T3 (es) 2004-04-01
HK1005982A1 (en) 1999-02-05
HU225963B1 (en) 2008-01-28
JPH07507054A (ja) 1995-08-03
IL104797A0 (en) 1993-06-10
AP9300492A0 (en) 1993-04-30
KR100334973B1 (ko) 2002-10-12
WO1993016733A1 (en) 1993-09-02
ATE244020T1 (de) 2003-07-15
HUT70440A (en) 1995-10-30
PT626864E (pt) 2003-11-28
DK0626864T3 (da) 2003-10-20
JP4005628B2 (ja) 2007-11-07
SG49874A1 (en) 1998-06-15
KR950700085A (ko) 1995-01-16
NZ299281A (en) 2000-12-22
CA2061566A1 (en) 1993-08-21
DE69333072D1 (de) 2003-08-07
HU9303283D0 (en) 1994-03-28
MX9300905A (es) 1993-10-01
HU211689A9 (en) 1995-12-28
AU4272900A (en) 2000-09-28
AU768058B2 (en) 2003-11-27
AP476A (en) 1996-03-18
EP0626864B1 (de) 2003-07-02
CA2061566C (en) 2002-07-09
EP0626864A1 (de) 1994-12-07
ZA931174B (en) 1993-09-16
NZ249072A (en) 1996-10-28
CZ9300229A3 (cs) 2002-06-12
SK11093A3 (en) 1993-09-09

Similar Documents

Publication Publication Date Title
CN1078388A (zh) 应用透明质酸和nsaids治疗疾病
CN1084064A (zh) 含有透明质酸的制剂
CN1102852C (zh) 含一氧化二氮的止痛药、消炎药和解热药的给药介质及含有这样的介质和药物的药物组合物
CN1051503A (zh) 病症与疾病的治疗
US10179159B2 (en) Topical anesthetic formulation
CN100346788C (zh) 用于鼻内给药的芬太尼组合物
CN1953743B (zh) 局部辅酶q10制剂及其使用方法
CN1304001C (zh) 含有硝基咪唑的皮肤病外用药
CN1198586C (zh) 用于递送nsai药物的局部用组合物
CN1791399A (zh) 用α2δ亚基钙通道调节剂和平滑肌调节剂一起治疗下泌尿道病症的方法
CN1930190A (zh) 透明质酸衍生物及含有其的药剂
US20140073691A1 (en) Methods and composition for Treating Thyroid Hormone Related Disorders
US20110257126A1 (en) Water soluble curcumin compositions for use in anti-cancer and anti-inflammatory therapy
CN1886126A (zh) 利用n－酰基－l－天冬氨酸的方法和产品
CN1434705A (zh) 氢氧根释放剂增强透皮渗透的用途
TW201242618A (en) Pharmaceutical cream compositions and methods of use
CN1358095A (zh) 使用mek抑制剂治疗慢性疼痛的方法
CN1255059A (zh) 治疗狗的疼痛和炎症的cox－2选择性咔洛芬
CN1630528A (zh) 含药用人参的脑细胞或神经细胞保护剂
US20150359740A1 (en) Composition and method for compounded therapy
AR074357A1 (es) Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. metodo de dialisis in vitro
US20200262794A1 (en) Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones
CN1571661A (zh) 遮味抗溢出制剂
US20220031612A1 (en) Uricase gel preparation for external use, preparation method therefor and use thereof
CN1694728A (zh) 用于传递治疗剂的以环糊精为基础的聚合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Applicant after: Hyal Pharmaceutical Corp.

Applicant before: Norpharmco Inc.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NORPHARMCO INC. TO: HYALOPLASM ACID PHARMACY CO., LTD.

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned